Spyre Therapeutics is a clinical-stage biotechnology company developing long-acting engineered monoclonal antibodies targeting validated immune pathways in inflammatory bowel disease and rheumatic diseases, including programs against α4β7, TL1A, and IL-23 designed to enable quarterly or twice-annual subcutaneous dosing. The company's pipeline includes monotherapy candidates and fixed-dose-combination therapies pairing complementary mechanisms intended to deliver superior efficacy and convenience compared to existing treatments. Spyre intends to commercialize approved products through internal infrastructure and external partnerships while outsourcing all manufacturing to third-party providers, targeting large markets with significant unmet medical needs in IBD, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, where it aims to establish first-in-class and best-in-class positioning.